The November 1, 2018, article by Cruz et al entitled “Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy” (J Clin Oncol 36:3134-3143, 2018) was published with errors in the AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST section.
Dr. Baselga’s COIs were given as:
José Baselga
Leadership: Varian Medical Systems, Bristol-Myers Squibb, Foghorn Therapeutics
Stock or Other Ownership: PMV Pharmaceuticals, GRAIL, Tango Therapeutics, Northern Biologics.
They should have read as:
José Baselga
Leadership: Varian Medical Systems, Bristol-Myers Squibb, GRAIL, Infinity Pharmaceuticals
Stock or Other Ownership: PMV Pharmaceuticals, GRAIL, Tango Therapeutics, Northern Biologics, Juno Therapeutics, Infinity Pharmaceuticals, Varian Medical Systems, Foghorn, Aura Biomedical, Apogen, Bristol-Myers Squibb
Honoraria: PMV pharma, Juno Therapeutics, Infinity Pharmaceuticals, GRAIL, Northern Biologics
Consulting or Advisory Role: Eli Lilly, Novartis
Research Funding: Roche
Patents, Royalties, Other Intellectual Property: Combination Therapy using PDK1 and PI3K inhibitors. Pending. MSK owned, listed as investigator. Use of phosphoinositide 3- kinase inhibitors for treatment of vascular malformations. Licensed. MSK owned, listed as investigator. May 16. Inhibition of KMT2D for the treatment of breast cancer. Pending. MSK owned, listed as investigator.
Travel, Accommodations, Expenses: Roche/Genentech, Daiichi, Bristol-Myers Squibb
This has been corrected as of January 11, 2019. The author apologizes for the errors.